<code id='7CF8B4EC8A'></code><style id='7CF8B4EC8A'></style>
    • <acronym id='7CF8B4EC8A'></acronym>
      <center id='7CF8B4EC8A'><center id='7CF8B4EC8A'><tfoot id='7CF8B4EC8A'></tfoot></center><abbr id='7CF8B4EC8A'><dir id='7CF8B4EC8A'><tfoot id='7CF8B4EC8A'></tfoot><noframes id='7CF8B4EC8A'>

    • <optgroup id='7CF8B4EC8A'><strike id='7CF8B4EC8A'><sup id='7CF8B4EC8A'></sup></strike><code id='7CF8B4EC8A'></code></optgroup>
        1. <b id='7CF8B4EC8A'><label id='7CF8B4EC8A'><select id='7CF8B4EC8A'><dt id='7CF8B4EC8A'><span id='7CF8B4EC8A'></span></dt></select></label></b><u id='7CF8B4EC8A'></u>
          <i id='7CF8B4EC8A'><strike id='7CF8B4EC8A'><tt id='7CF8B4EC8A'><pre id='7CF8B4EC8A'></pre></tt></strike></i>

          hotspot

          hotspot

          author:explore    Page View:53171
          European Medicines Agency Suffers Cyber Attack in Amsterdam
          Paulo Amorim / VWPics via AP Images

          LONDON — European regulators on Friday reiterated their view that an ALS treatment from Amylyx Pharmaceuticals should not be approved, likely dooming the drug’s chances for now. 

          A European Medicines Agency committee had initially recommended against approving the drug, known as Albrioza, in June. Friday’s confirmation of that position came after the company appealed the decision. While the European Commission officially decides whether to approve a new medicine, it almost always follows the committee’s guidance. The final decision is expected to be made before the end of the year. 

          advertisement

          The drug, which won approval last year in the United States and is marketed Relyvrio, is designed to slow the progression of the fatal neurological condition. In its pivotal trial, patients who received the drug over 24 weeks scored about two points better on a 48-point scale of symptoms than those who got a placebo, indicating the drug slowed disease progression.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          explore

          As demand for Covid shots wanes, Moderna seeks its next success
          As demand for Covid shots wanes, Moderna seeks its next success

          RubyWallauforSTATModernachairmanNoubarAfeyanexudedstarpowerearlierthismonthashecommandedthespotlight

          read more
          Europe sees delivery challenges ahead on Alzheimer's therapies
          Europe sees delivery challenges ahead on Alzheimer's therapies

          VialsandpackagingforLeqembi,anewAlzheimer'smedicationapprovedintheU.S.,butnotyetinEurope.Illustratio

          read more
          Guidelines to prevent youth baseball injuries need more muscle
          Guidelines to prevent youth baseball injuries need more muscle

          Apitcheratthe2018LittleLeagueWorldSeries.RobCarr/GettyImages“Weallknowthatweareinthemiddleofanepidem

          read more

          Artificial intelligence use in health care faces greater scrutiny in 2024

          AdobeIfthepastyearwasprelude,theU.S.governmentin2024ispoisedtore-writetherulessurroundingtheuseofart